157 related articles for article (PubMed ID: 34041707)
41. Registries in European post-marketing surveillance: a retrospective analysis of centrally approved products, 2005-2013.
Bouvy JC; Blake K; Slattery J; De Bruin ML; Arlett P; Kurz X
Pharmacoepidemiol Drug Saf; 2017 Dec; 26(12):1442-1450. PubMed ID: 28345151
[TBL] [Abstract][Full Text] [Related]
42. A Decade of Marketing Authorization Applications of Anticancer Drugs in the European Union: An Analysis of Procedural Timelines.
Garsen M; Steenhof M; Zwiers A
Ther Innov Regul Sci; 2021 Jul; 55(4):633-642. PubMed ID: 33543409
[TBL] [Abstract][Full Text] [Related]
43. The European Medicines Agency facilitates access to medicines in low- and middle-income countries.
Cavaller Bellaubi M; Harvey Allchurch M; Lagalice C; Saint-Raymond A
Expert Rev Clin Pharmacol; 2020 Mar; 13(3):321-325. PubMed ID: 32053756
[No Abstract] [Full Text] [Related]
44. More medicines for children: impact of the EU paediatric regulation.
Nordenmalm S; Tomasi P; Pallidis C
Arch Dis Child; 2018 Jun; 103(6):557-564. PubMed ID: 29490933
[TBL] [Abstract][Full Text] [Related]
45. The contribution of field efficacy studies to the evaluation of applications for veterinary vaccines evaluated through the European Union centralised authorisation procedure.
Mackay D; Jimenez CM; Ioannou F; Ilott M
Biologicals; 2021 Apr; 70():7-16. PubMed ID: 33840590
[TBL] [Abstract][Full Text] [Related]
46. Similarities and differences in the oncology drug approval process between FDA and European Union with emphasis on in vitro companion diagnostics.
Senderowicz AM; Pfaff O
Clin Cancer Res; 2014 Mar; 20(6):1445-52. PubMed ID: 24634467
[TBL] [Abstract][Full Text] [Related]
47. The notorious "drug lag" for oncology drugs in Japan.
Yonemori K; Hirakawa A; Ando M; Hirata T; Yunokawa M; Shimizu C; Katsumata N; Tamura K; Fujiwara Y
Invest New Drugs; 2011 Aug; 29(4):706-12. PubMed ID: 21286780
[TBL] [Abstract][Full Text] [Related]
48. [How does a new medicine reach the patient?].
Visser BJ; Korevaar DA; Mokhles MM; Vermeer-Pragt W; de Boer A; Giezen TJ
Ned Tijdschr Geneeskd; 2020 Jul; 164():. PubMed ID: 32779914
[TBL] [Abstract][Full Text] [Related]
49. Advanced Therapy medicinal products for autologous chondrocytes and comparison of regulatory systems in target countries.
Kim J; Park J; Song SY; Kim E
Regen Ther; 2022 Jun; 20():126-137. PubMed ID: 35582708
[TBL] [Abstract][Full Text] [Related]
50. Adaptive clinical trial designs for European marketing authorization: a survey of scientific advice letters from the European Medicines Agency.
Elsäßer A; Regnstrom J; Vetter T; Koenig F; Hemmings RJ; Greco M; Papaluca-Amati M; Posch M
Trials; 2014 Oct; 15():383. PubMed ID: 25278265
[TBL] [Abstract][Full Text] [Related]
51. The European Medicines Agency review of Tegafur/Gimeracil/Oteracil (Teysuno™) for the treatment of advanced gastric cancer when given in combination with cisplatin: summary of the Scientific Assessment of the Committee for medicinal products for human use (CHMP).
Matt P; van Zwieten-Boot B; Calvo Rojas G; Ter Hofstede H; Garcia-Carbonero R; Camarero J; Abadie E; Pignatti F
Oncologist; 2011; 16(10):1451-7. PubMed ID: 21963999
[TBL] [Abstract][Full Text] [Related]
52. Predictors of orphan drug approval in the European Union.
Heemstra HE; de Vrueh RL; van Weely S; Büller HA; Leufkens HG
Eur J Clin Pharmacol; 2008 May; 64(5):545-52. PubMed ID: 18210097
[TBL] [Abstract][Full Text] [Related]
53. Potential Procedural Efficiencies and Challenges of Combining Multiple Type II Variations into a Single EU-RMP.
Marshall R; Atuah KN; Tekumalla SH
Pharmaceut Med; 2020 Feb; 34(1):1-5. PubMed ID: 32048215
[TBL] [Abstract][Full Text] [Related]
54. A Sequel to the Eteplirsen Saga: Eteplirsen Is Approved in the United States but Was Not Approved in Europe.
Aartsma-Rus A; Goemans N
Nucleic Acid Ther; 2019 Feb; 29(1):13-15. PubMed ID: 30526286
[TBL] [Abstract][Full Text] [Related]
55. Marketing authorisations for unmet medical needs: A critical appraisal of regulatory pathways in the European Union.
Manellari S; Musazzi UM; Rocco P; Minghetti P
Int J Pharm; 2023 Jul; 642():123193. PubMed ID: 37394157
[TBL] [Abstract][Full Text] [Related]
56. The Small- and Medium-sized Enterprises Office (SME Office) at the European Medicines Agency.
Carr M
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):20-3. PubMed ID: 20101799
[TBL] [Abstract][Full Text] [Related]
57. Hurdles in gene therapy regulatory approval: a retrospective analysis of European Marketing Authorization Applications.
Carvalho M; Martins AP; Sepodes B
Drug Discov Today; 2019 Mar; 24(3):823-828. PubMed ID: 30579785
[TBL] [Abstract][Full Text] [Related]
58. Old active ingredients in new medicinal products: is the regulatory path coherent with patients' expectations?
Minghetti P; Musazzi UM; Casiraghi A; Rocco P
Drug Discov Today; 2020 Aug; 25(8):1337-1347. PubMed ID: 32485225
[TBL] [Abstract][Full Text] [Related]
59. Available Tools to Facilitate Early Patient Access to Medicines in the EU and the USA: Analysis of Conditional Approvals and the Implications for Personalized Medicine.
Leyens L; Richer É; Melien Ø; Ballensiefen W; Brand A
Public Health Genomics; 2015; 18(5):249-59. PubMed ID: 26316202
[TBL] [Abstract][Full Text] [Related]
60. The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: A cross-sectional study of products authorised 2011-2018.
Schuster Bruce C; Brhlikova P; Heath J; McGettigan P
PLoS Med; 2019 Sep; 16(9):e1002873. PubMed ID: 31504034
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
